Innate Pharma SA (IPHA)

Nasdaq Biotechnology Diagnostics SIC: 2836
A
Pipeline Grade

Drug Pipeline (1 Assets)

DrugPhaseIndications
MOXETUMOMAB PASUDOTOX-TDFK
LUMOXITI 		APPROVED —

Upcoming Catalysts

DateEventDrug
2026-09-30 Phase2 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05857930 A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing PHASE2 Active Not Recruiting 296

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for IPHA.

SEC EDGAR Filings

All SEC filings for Innate Pharma SA on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.